Studies On The Expression And Immunogenicity Of The Modified Human Papillomavirus Type 16 E6/E7 Fusion Protein As Well As Its Antitumor Effacacy

Cervical cancer is the first commonest gynecologic malignance in the world with 50,000 cases diagnosed annually, among which more than 80% cases occurred in the developing country. Increasing evidences demonstrated that cervical cancer is highly associated with the infection of human papillomavirus (HPV), about 90% specimen from cervical cancers contain HPV DNA, among which HPV16 is the most prevalent, accounting for abount 60% cervical cancers. Therefore, persistent infection with HPV has been identified as one of the most dangerous risk for development of cervical cancer. In addition, increasing evidences indicate that HPVs are also associated with other tumors. HPVs DNA have been detected in vulval cancer, genital cancer, lung cancer, ovarian cancer, esohpageal cancer, and so on. So it is very important to develop the efficient and cheap vaccine for prevention from HPV infection and CIN and treatment of cervical cancer as well as other cancers associated with HPV.HPV16 E6 and E7 are two ocongenes, the oncoproteins play a key role for the induction and maintenance of the transformation phenotype. In addition, because they are constitutively expressed in cervical cancer and CIN, they are tumor-specific antigens and serve as ideal targets for the development of immunotherapy to prevent and treat HPV-16 associated CIN and cervical cancer, and has been become the research hot of HPV therapeutic vaccine. Now, most of therapeutic vaccines against HPV are focused on the HPV16 E7 oncoprotein in the world. Since HPV E6 is another important tumor specific antigen, an optional protein-based vaccine would comprise the HPV E6 and E7 protein. However, the expression level of wild type HPV16 E6/E7 fusion protein was very low, and the in vivo antitumor efficacy of the HPV16 E6/E7 fusion protein has not...